Sotrovimab (Xevudy®) – COVID-19, ≥ 12 years

Characteristics

Start date 15.05.2022
Resolution 03.11.2022
INN Sotrovimab
Brand name Xevudy®
Pharm. company GlaxoSmithKline GmbH & Co. KG
G-BA procedure ID 2022-05-15-D-817
ATC code J06BD05
ICD-10 codes J06.9Upper respiratory disease, acute
Therapeutic area Infectious diseases
Reason for procedure Initial assessment
Specialty ACT change

G-BA resolution "Anwendungsgebiet des Beschlusses" (German)

Xevudy is indicated for the treatment of adults and adolescents (12 years of age and older and weighing at least 40 kg) with coronavirus disease-2019 (COVID-19) who do not require oxygen supplementation and are at increased risk for severe disease progression of COVID-19

Subpopulation Indication Comparator
a) Adults with COVID-19 disease who do not require supplemental oxygen therapy and who are at increased risk for a severe course of COVID-19 in the case of infection with a infection with a viral variant against which sotrovimab has significantly reduced or significantly reduced or insufficient efficacy Treatment according to physicisan's choice
b) Adults with COVID-19 disease who do not require supplemental oxygen therapy and who are at increased risk for a severe course of COVID-19, in the setting of infection with a viral variant against which sotrovimab has sufficient efficacy Treatment according to physicisan's choice
c) Adolescents 12 to <18 years of age and older with at least 40 kg body weight with COVID-19 disease who do not require supplemental oxygen therapy and who are at increased risk for a severe course of COVID-19 Treatment according to physicisan's choice

9. Associated procedures

Resolution INN Brand name Indication Patients Additional benefit
Sotrovimab Xevudy® COVID-19, ≥ 12 years 3
0


<< List of all resolutions

Log in to read more ...

The AMNOG monitor is a subscription-based service for pharmaceutical manufacturers and institutions. Enter your account details here in order to analyse the results of the early benefit assessment in Germany – or contact us for more information.